Artificial intelligence is revolutionizing the pharmaceutical industry by predicting complex protein structures. However, this abundance of potential drugs has created a bottleneck in characterizing them for testing and production.

Enter 10x Science, a recently funded startup with a mission to streamline this process. Founded by experienced biochemists and a serial tech entrepreneur, the company is developing algorithms that can interpret mass spectrometry data, a technique used to determine molecular structures.

The key innovation lies in combining deterministic chemistry and biology models with AI interpretation. The team has trained these models on extensive data sets, ensuring they are both accurate and user-friendly. This approach not only saves time but also enhances the reliability of drug development.

Matthew Crawford, a scientist at Rilas Technologies, has been using 10x Science’s platform and finds it impressively adept at explaining its conclusions and adapting to different types of molecules without over-promising or under-delivering on accuracy.

The startup is also collaborating with major pharmaceutical companies and academic researchers. With seed funding in hand, 10x plans to expand its services, offering a novel understanding of biology that could revolutionize the drug development process beyond mere characterization.